Related Experiment Video
Updated: Jun 9, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Targeting head and neck squamous cell carcinoma using a novel fusion toxin-diphtheria toxin/HN-1
1Stem Cell & Molecular Biology Laboratory, Department of Biotechnology, Indian Institute of Technology Madras, #201, Bhupat and Jyoti Mehta School of Biosciences Building, Chennai, 600036, India.
Abstract:
The current treatment strategies, chemotherapy and radiation therapy being used for the management of cancer are deficient in targeted approach leading to treatment related toxicities and relapse. Contrarily, fusion toxins exhibit remarkable tumor specificity thus emerging as an alternative therapy for the treatment of cancer. Diphtheria toxin-HN-1 peptide (DT/HN-1) is a fusion toxin designed to target the head and neck squamous cell carcinoma (HNSCC). The aim of this study was to construct, characterize, and evaluate the cytotoxicity and specificity of DT/HN-1 fusion toxin against the HNSCC cells. The purified DT/HN-1 fusion toxin was characterized by SDS-PAGE and western blotting. Refolding of purified fusion toxins was monitored by fluorescence spectra and circular dichroism spectra. The activity of DT/HN-1 fusion toxin was demonstrated on various HNSCC cell lines by cell viability assay, cell proliferation assay, protein synthesis inhibition assay, apoptosis and cell cycle analysis. The fusion toxin DT/HN-1 demonstrated remarkably high degree of cytotoxicity specific to the HNSCC cells. The IC(50) of DT/HN-1 fusion toxin was ~1 to 5 nM in all the three HNSCC cell lines. The percentage apoptotic cells in DT/HN-1 treated UMB-SCC-745 cells are 16% compared to 4% in untreated. To further demonstrate the specific toxicity of DT/HN-1 fusion toxin towards the HNSCC cells we constructed, characterized and evaluated the efficacy of DT protein. The DT protein coding for only a fragment of diphtheria toxin without its native receptor binding domain failed to exhibit any cytotoxicity on all the cell lines used in this study thus establishing the importance of a ligand in achieving targeted toxicity. To evaluate the translocation ability of HN-1 peptide, an additional construct DTΔT/HN-1 was constructed, characterized and evaluated for its cytotoxic activity. The fusion toxin DTΔT/HN-1 deficient of the translocation domain of diphtheria toxin showed no cytotoxicity on all the cell lines clearly indicating the inability of HN-1 peptide to translocate catalytic domain of the toxin into the cytosol.
Insights
Fusion toxins like diphtheria toxin-HN-1 peptide offer targeted cancer therapy for head and neck squamous cell carcinoma (HNSCC). This study confirms DT/HN-1
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Conventional cancer treatments (chemotherapy, radiation) lack specificity, leading to toxicity and relapse.
- Fusion toxins present a promising alternative due to their tumor-specific targeting capabilities.
- Diphtheria toxin-HN-1 peptide (DT/HN-1) is engineered for head and neck squamous cell carcinoma (HNSCC) management.
Purpose of the Study:
- To construct and characterize the DT/HN-1 fusion toxin.
- To evaluate the cytotoxicity and specificity of DT/HN-1 against HNSCC cells.
- To elucidate the role of the HN-1 peptide and diphtheria toxin's translocation domain in targeted toxicity.
Main Methods:
- Purification and characterization of DT/HN-1 using SDS-PAGE and Western blotting.
- Assessment of refolding using fluorescence and circular dichroism spectroscopy.
- Evaluation of cytotoxicity, proliferation inhibition, protein synthesis inhibition, apoptosis, and cell cycle effects on HNSCC cell lines.
Main Results:
- DT/HN-1 demonstrated potent and specific cytotoxicity against HNSCC cell lines with IC(50) values of 1-5 nM.
- DT/HN-1 induced significant apoptosis (16%) in HNSCC cells compared to controls (4%).
- Constructs lacking the native receptor-binding domain or translocation domain showed no cytotoxicity, highlighting the importance of ligand-mediated targeting and translocation.
Conclusions:
- DT/HN-1 fusion toxin exhibits high specificity and potent cytotoxicity against HNSCC.
- The HN-1 peptide is crucial for targeting, and the diphtheria toxin's translocation domain is essential for intracellular delivery and activity.
- DT/HN-1 represents a viable targeted therapy candidate for HNSCC.
More Related Videos
08:55Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018